Coagulation Disorders near Englewood, NJ

Care Philosophy: The ability to work closely with patients and with specialists in a variety of fields to solve complex clinical questions draws me to the field of non-malignant hematology. I am lucky to have had the opportunity to train under brilliant thinkers and exceptional role models from whom I have learned the importance of ensuring that each patient truly understands his or her diagnosis and the rationale behind treatment. I am excited to be joining the Department of Hematology at Weill Cornell and look forward to continuing in clinical investigations in hopes of improving diagnosis and treatment in the fields of thrombosis and immune thrombocytopenia. We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Joseph Jurcic is a Professor of Medicine at Columbia University Medical Center and the Director of the Hematologic Malignancies Section within the Division of Hematology/Oncology. He specializes in Medical Oncology and focuses on leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Based in New York, NY, Dr. Jurcic is affiliated with NewYork-Presbyterian/Columbia University Irving Medical Center. He received his M.D. from the Perelman School of Medicine at the University of Pennsylvania and completed his training at Barnes-Jewish Hospital and Memorial Sloan Kettering Cancer Center. He is board-certified in both Medical Oncology and Hematology.Dr. Jurcic's clinical expertise includes the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndromes. His research interests encompass acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy, developing novel small molecule inhibitors, and molecular monitoring of minimal residual disease. Recognized as one of New York Magazine's "Best Doctors" from 2014 to 2024, he has authored or co-authored over 80 articles and book chapters. He has served as the principal investigator on more than 25 clinical trials. Additionally, Dr. Jurcic lectures at national and international conferences and is the Leukemia Section Editor for The Oncologist.

Biography: Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia. She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases. She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.

Biography: Margaret T Lee, MD cares for children with blood disorders, such as anemias (sickle cell anemia, thalassemia, and iron deficiency), bleeding (including idiopathic thrombocytopenic purpura [ITP], hemophilia, and von Willebrand disease), and clotting disorders (such as deep vein thrombosis). Dr. Lee's area of interest is a rare group of diseases called vascular anomalies. There is relatively little known about these disorders, and the care of patients with vascular anomalies requires a multidisciplinary group of physicians from several specialties (dermatology, surgery, cardiology, neurology, and hematology/oncology)-all of whom are available at NewYork-Presbyterian/Morgan Stanley Children's Hospital. Hematologists play a role in the medical treatment of vascular tumors and the supportive care of clotting and bleeding complications that are associated with some types of vascular malformations. Dr. Lee is an active participant in the Vascular Anomalies Group at NYP/Morgan Stanley Children's Hospital, as well as the Vascular Anomalies Special Interest Group of the American Society of Pediatric Hematology/Oncology, which is looking at novel therapies for vascular anomalies and their complications.

Biography: Andrew Eisenberger graduated from Columbia University with a BA in Philosophy in 1992 and received his MD from Albert Einstein College of Medicine in 2001. Dr. Eisenberger did his residency in internal medicine at Montefiore Medical Center, where he served for a year as chief resident. He then completed his fellowship in Hematology/Oncology at New York Presbyterian Hospital/Columbia University Medical Center. Dr. Eisenberger embraces his role as a medical educator: for medical students, physicians in training, colleagues and patients alike. The Columbia University Vagelos School of Physicians and Surgeons' Hematology course has been under his leadership for more than a decade, and he recently became an associate program director of the University's Hematology/Oncology post-doctoral fellowship program. Dr. Eisenberger was inducted into the Medical Center's Academy of Clinic Excellence in 2018. His clinical practice currently focuses on the diagnosis and management of complex bleeding and clotting disorders, particularly in unique populations such as pregnant women and critically ill hospitalized patients. He also has extensive experience with difficult-to-manage blood disorders including antiphospholipid antibody syndrome (APLS), heparin-induced thrombocytopenia (HIT), immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), thrombotic thrombocytopenic purpura (TTP), hematologic complications of solid organ transplantation and myeloproliferative neoplasms.